1. Introduction {#s0005}
===============

Selective serotonin reuptake inhibitors (SSRIs) are one of the most commonly prescribed psychotropic medications but the clinical significance of this class of drugs has been widely debated in the field of depression ([@bb0045]; [@bb0115]) and anxiety ([@bb0160]; [@bb0195]). In depression, this debate has been fueled by meta-analytic studies failing to demonstrate a clinically meaningful advantage of SSRIs over placebo ([@bb0120]) although superior SSRI (\> placebo) effects have been noted, e.g. in severely depressed patients ([@bb0045]; [@bb0115]) and when limiting statistical analyses to depressed mood as a single-item measure ([@bb0105]). It has even been argued that improvement attributed to antidepressants in double-blind trials could reflect an enhanced placebo response, i.e., beneficial outcome unrelated to the specific/active properties of the treatment itself, due to treatment expectations induced by perceived side effects ([@bb0145]). Indeed, previous research in anxiety ([@bb0055]), depression ([@bb0050]; [@bb0175]) and pain ([@bb0040]; [@bb0055]) supports that the patients\' expectancies and beliefs can have a profound influence on therapeutic outcomes. However, with regard to the SSRI vs. placebo minimal difference debate, conclusions have been based mostly on meta-analytic ([@bb0120]) and correlational studies ([@bb0050]), hampering causal inference.

Here, we tested how verbally induced expectancies, a crucial placebo mechanism, influence SSRI efficacy in patients with social anxiety disorder (SAD). Treatment studies of SAD have noted response rates of about 50--60% for SSRIs like escitalopram and 40% for placebo ([@bb0025]). In a previous neuroimaging trial of SAD we found striking similarities between SSRI and placebo responders both regarding clinical effects and altered anxiety-related brain activity ([@bb0060], [@bb0065]). However, previous studies could not fully infer about the influence of expectancies on SSRI treatment outcome because expectancies have not been measured and experimentally manipulated. Thus, in the present study, we experimentally addressed the question raised by meta-analytic studies i.e., to what extent the clinical effects of SSRIs can be manipulated by verbal suggestions. Patients with SAD were treated with equivalent doses of escitalopram (20 mg daily) for 9 weeks, but only one group was correctly informed about the treatment received and its effectiveness. By use of a credible cover story, the other group was led to believe that they were treated with an "active placebo" (neurokinin-1 antagonist) that lacked specific anxiolytic properties, but was expected to induce side effects similar to the SSRI.

Thus, the aim was to assess the clinical efficacy of escitalopram with and without expectations of improvement, i.e. overt vs. covert SSRI treatment. To evaluate effects also on objective brain parameters, neural reactivity to a disorder-relevant emotional face-matching task ([@bb0100]; [@bb0095]) was assessed before and at the last week of treatment with functional magnetic resonance imaging (fMRI). Based on reports of a strong placebo effect in SAD treatment ([@bb0025]; [@bb0060], [@bb0065]) and the association between SAD symptoms and amygdala reactivity ([@bb0060], [@bb0065]; [@bb0090]; [@bb0095]), we expected larger clinical improvement and greater attenuation of amygdala responsivity in the overt as compared to covert SSRI group.

2. Materials and Methods {#s0010}
========================

2.1. Study Design and Participants {#s0015}
----------------------------------

This was an investigator-initiated, randomized, clinical trial on escitalopram with manipulation of verbal instructions i.e., expectancies, conducted in an academic medical centre (Uppsala, Sweden). Patients with SAD were randomized into two treatment arms but all received equal doses of 20 mg escitalopram per day for nine weeks (10 mg the first week). However, whereas patients in the overt treatment arm were correctly informed about the treatment received, patients in the covert arm were deceived with a cover story (see procedure, expectancy manipulation).

The Regional Ethical Review Board, Uppsala and the Medical Products Agency in Sweden approved the study which complied with the standards established by the Declaration of Helsinki. All participants were provided with verbal and written instructions about the study procedure and objectives, comparing escitalopram and "active placebo". The stated purpose of evaluating active placebo was to acquire knowledge about its neural effects, for later use as an improved control treatment in clinical trials. All participants gave written informed consent prior to inclusion. Participants in the covert group were debriefed by the study psychiatrist at unblinding. For ethical reasons, all participants were also offered an internet-based cognitive behavioral therapy (CBT) program ([@bb0015]) for free after initial treatment.

Participants (aged 18 years and older) were recruited through newspaper advertisements and public billboards. During the initial screening, the Social Phobia Screening Questionnaire (SPSQ) ([@bb0085]) and the Montgomery Åsberg Depression Rating Scale (MADRS-S) ([@bb0150]) were administered online. Participants passing initial screening were interviewed using the Mini International Neuropsychiatric Interview (MINI) ([@bb0185]), the SAD section of the Structured Clinical Interview for DSM-IV (SCID-I) ([@bb0070]), and underwent a medical check-up. All participants had to meet the DSM-IV ([@bb0010]) criteria for SAD as the primary diagnosis. Exclusion criteria were: contraindications for MR, age \< 18 or \> 65 years, presence of severe somatic disease or serious psychiatric disorder such as psychosis or severe major depression, treatment for any psychiatric disorder (ongoing or terminated within three months), pregnancy, menopause, and drug or alcohol abuse/dependency.

2.2. Randomization and Masking {#s0020}
------------------------------

Randomization, stratified by sex and age, was determined by a computerized random-number generator in blocks of two by an independent third party (APL, Stockholm, Sweden). The treating psychiatrist of the study (K.W.) assigned participants to the trial, after baseline measurements and consent, and allocation to intervention was implemented by use of a numbered list. Randomization codes were kept secret, in a sealed opaque envelope, at the psychiatrist\'s clinic until study completion. APL, Stockholm, Sweden, prepared standard escitalopram tablets for the overt group, and unmarked capsules for the covert group, both containing escitalopram 20 mg (Cipralex, H. Lundbeck AB, Helsingborg, Sweden) which were placed in containers marked with "Active placebo/Escitalopram 20 mg" (10 mg first week). Due to the nature of the investigation, the treating psychiatrist (K.W.) was not blinded while the research staff was blinded to the intervention allocation after randomization.

To minimize experimenter influence, the primary outcome measure i.e., the Liebowitz Social Anxiety Scale self-rate version (LSAS-SR) ([@bb0075]) with automated scoring, was filled out online at home and participants were instructed not to reveal their allocated treatment to assessors. After the final assessments, before unblinding, all personnel in the study completed a short written questionnaire with the following (yes/no) questions: 1. During the study, did you know treatment allocation for any of the participants? (If yes, for how many?); 2. Did any of the participants disclose information of any type that revealed their allocated treatment to you? According to the questionnaire, none of the personnel in the trial, beside the non-blinded psychiatrist (K.W.), reported knowledge about group allocation for any participant.

2.3. General Procedure {#s0030}
----------------------

After initial screening, baseline measurements and consent, two fMRI scanning sessions with an emotional face-matching task were scheduled for each participant, one before and one at the end, during the last week, of treatment. At the end of each fMRI-session, participants were exposed to a public speaking behavioral test in which they gave a two minute speech on a freely chosen topic in front of a silent audience (5--8 persons) -- see [@bb0095]. Anticipatory anxiety was assessed with the Spielberger State-Trait Anxiety Inventory - State version (STAI-S) ([@bb0190]) before the speech. All participants were informed, prior to signing the informed consent, that they were requested to hold a speech after each fMRI-session. Before and during week 1, 3, 6, and 9 of treatment, participants filled out the primary outcome LSAS-SR ([@bb0075]) online at home.

After the posttreatment fMRI scanning session, participants revisited the psychiatrist for a complementary clinical evaluation. Approximately 6 months after this visit, the participants in the covert group were contacted again by the psychiatrist and the cover story was revealed (see Supplement). After treatment, and at unblinding, participants were offered further contact with the psychiatrist at own cost and access to a free internet CBT program ([@bb0015]). Efficacy of the internet CBT program offered to all participants after initial treatment was not assessed due to low numbers of completers.

2.4. Expectancy Manipulation {#s0035}
----------------------------

After the first fMRI session, an experienced psychiatrist (K.W.) assessed additional baseline clinical symptom severity (see Supplement), and the participants were handed their supply of daily escitalopram 20 mg (10 mg first week) with separate verbal instructions for the overt and covert arm. The overt group was correctly informed about the SSRI treatment and the expected improvement, whereas the covert group were told that they would receive the active placebo, i.e. a non-functioning neurokinin-1 antagonist (GW597599) likely to induce side effects similar to escitalopram but out of which no symptom-improvement could be expected (see the Supplementary appendix for the full written and verbal information to participants). Participants revisited the psychiatrist\'s clinic after one week and were then handed their supply of the medication for the remainder of the study period. Compliance was assessed by serum drug concentrations at the posttreatment fMRI.

2.5. Functional Magnetic Resonance Imaging {#s0040}
------------------------------------------

MR imaging was performed using a Philips Achieva 3.0 T whole body MR-scanner (Philips Medical Systems, Best, The Netherlands) equipped with an 8-channel head-coil. Five of the participants (three in the overt and two in the covert group) were scanned after an upgrade of the scanner software and for those participants a 32-channel head coil was used. Participants were positioned supine in the scanner. An anatomical T1-weighted image (echo time(TE) = 15 ms; repetition time (TR) = 5700 ms; inversion time = 400 ms; field of view = 230 × 230 mm^2^; voxel size = 0.8 × 1.0 × 2.0 mm^3^; 60 contiguous slices) and a blood‑oxygenation-level dependent (BOLD) echo planar imaging (EPI) sequence (TE = 35 ms; TR = 3000 ms; flip angle = 90°, acquisition matrix = 76 × 77, voxel size = 3.0 × 3.0 × 3.0 mm^3^, gap = 1 mm, 30 axial slices) was acquired. Visual stimuli were presented through goggles (Visual System, NordicNeuroLab, Bergen, Norway) using *E*-prime (Psychology Software Tools, Sharpsburg, PA, USA).

2.6. fMRI Paradigm {#s0045}
------------------

The paradigm included matching of fearful or angry facial expressions and geometrical shapes ([@bb0100]). In each trial, a target face or shape was displayed at the top of the screen and, by pressing a button with their left or right index finger, the participants indicated which one of two lower images displayed the same emotion or shape as the target (see Supplement, Fig. S1). Face and shape trials were presented in blocks of 6, in which images were presented for 4 s, interspaced with a fixation cross (2s for shape trials and a random duration of 2, 4, or 6s for face trials). The expressed emotion or shape of the target varied from trial to trial, and each face block had an equal mix of emotions as well as sex of the faces. Accuracy and reaction times were recorded but there were no significant group differences on these measures. The fMRI session included four additional scans not reported in the present study.

2.7. Primary Outcome Measures {#s0055}
-----------------------------

The main clinical outcome measure was the continuous LSAS-SR ([@bb0075]) (assessed online 5 times), which was also used to determine response status according to the criteria for clinically significant improvement ([@bb0110]). Responders exhibited a reliable change index \> 1.96 and a posttreatment total score \< 39, falling within 2 SD from the mean of the normal population ([@bb0075]). Further, anticipatory speech anxiety was assessed after each fMRI-session with the STAI-S ([@bb0190]), after three minutes of preparation.

2.8. Secondary Outcome Measures {#s0060}
-------------------------------

Before and after the full treatment period, five secondary outcome measures were also administered online: the Social Interaction Anxiety Scale (SIAS) ([@bb0135]), Social Phobia Scale (SPS) ([@bb0135]), MADRS-S ([@bb0150]), Beck Anxiety Inventory (BAI) ([@bb0030]), and the Quality of Life Inventory (QOLI) ([@bb0080]).

2.9. Credibility Ratings {#s0065}
------------------------

Before the first fMRI-session and after nine weeks of treatment, participants rated their treatment beliefs both about escitalopram and "active placebo". Questions, asked before the first scanning session, i.e., prior to randomization, included how logical the treatment seemed; how sure the patients were that they would be improved in symptomatology by the treatment; how strongly they would recommend the treatment to a friend in a similar situation; how they thought that the treatment would affect other types of anxiety disorders; how much improvement they would expect themselves if given the described treatment. All questions were rated between 0 and 10, 0 indicating "not at all" and 10 "very much". The results of these questions were used to create a summed credibility score (0--50) for each treatment.

At posttreatment, participants answered two questions regarding the perceived value of having been part of the study, one open and one with fixed rating steps (1 = not valuable, 2 = slightly valuable or neutral, 3 = rather valuable, 4 = very valuable). They were also asked how sure they were that the treatment they had been assigned to was effective for SAD and how strongly they would recommend the treatment to a friend with similar symptoms, both rated between 0 and 10, 0 indicating "not at all" and 10 "very much". In addition to this they responded to an open question whether their view of the effectiveness of the treatment they had received had changed during the study period (recoded into 1 = more negative, 2 = slightly more negative, 3 = none, 4 = slightly more positive, 5 = more positive).

Credibility/expectancy assessments were not performed continuously during treatment to avoid causing suspicion regarding the cover story. Participants in the covert group were also asked to rate their beliefs at the follow-up psychiatric appointment when the cover story was revealed (see the Supplement). Ratings were not available from 4 individuals.

2.10. fMRI Outcome {#s0070}
------------------

Estimates of blood-oxygen-level-dependent (BOLD) reactivity was obtained for each participant and session, by contrasting emotional faces against geometrical shapes. Change in this reactivity with treatment was then calculated for each participant and compared across groups (see below).

2.11. Power Calculations {#s0080}
------------------------

Assessing the effect of verbally-induced expectations on SSRI-treatment is a novel approach but power calculations based on previous placebo controlled SSRI trials ([@bb0060], [@bb0065]; [@bb0095]) assumed a difference between treatment arms in mean ± SD LSAS-scores of 11.4 ± 11.7. Given α = 0.05 and *n* = 24 per group, the study had 80% power to detect a difference between treatments.

2.12. Analyses of Behavioral Data {#s0085}
---------------------------------

Demographic and pretreatment clinical data were compared between groups by *t*-tests, Mann-Whitney *U* tests or Chi-square tests using IBM SPSS Statistics 20. Clinical treatment effects were evaluated using repeated measure MANOVA/ANOVA with t-test for follow-up analyses. For 3 (1%) missing LSAS-SR scores (*n* = 1 week3, n = 2 week 6) the last observation was carried forward. The standardized mean difference (Cohen\'s *d* pre-post) was also calculated for each group. For behavioral and demographic analyses, a *p*-value of \< 0.05 was considered significant. Statistical analyses were based on participants with complete outcome data, thereby excluding one early drop-out (male) in the covert group. A data monitoring delegate oversaw the study.

2.13. Analyses of Imaging Data {#s0090}
------------------------------

The fMRI-data were analysed in MATLAB (MathWorks, Natick, MA, USA) using SPM8 (<http://www.fil.ion.ucl.ac.uk/spm/software/spm8>). Each participant\'s BOLD EPI images were realigned to the mean image of each session, slice timing corrected to the middle slice of each volume, co-registered with the anatomical scan and normalized to Montreal Neurological Institute (MNI) standard space using parameters obtained from unified segmentation of the anatomical image. Finally, smoothing was performed using an 8 mm Gaussian kernel (full width, half maximum). The BOLD signal in each voxel was high-pass filtered with 128 s, regressed on the stimulus function (boxcar, onsets and durations of face- and shape-stimuli), six movement parameters obtained from the realignment step, and convolved with the canonical hemodynamic response function provided by SPM.

Individual difference images, representing changes in BOLD reactivity (emotional faces vs. shapes), were calculated by subtracting the pretreatment from the posttreatment contrast map, and used in second level group comparisons.

Between-groups t-tests were used to analyse the neural reactivity-changes with treatment. Comparisons in the automated anatomical labeling library (aal) region of interest (ROI) for bilateral amygdala were assessed at p \< 0.05 FWE-corrected for multiple comparisons. In addition to this, we used an exploratory whole brain approach with p \< 0.001 and a cluster extent of ≥ 10 voxels. Follow-up analyses of associations between symptom improvement and altered BOLD reactivity in the amygdala and the observed clusters from the exploratory whole brain analysis, were assessed in the whole sample by including LSAS-SR change scores in regression analyses at *p* \< 0.05. Follow-up analyses were also performed to assess group differences using psychophysiological interaction (PPI) analyses of amygdala connectivity with time-series fMRI data extracted from obtained peak voxels entered as a regressor together with task (faces vs. shapes) and the interaction between the two. For all fMRI-analyses time point of scanning (before/after upgrade) was used as a covariate. Spatial localizations are reported in Montreal Neurological Institute (MNI) coordinates.

3. Results {#s0095}
==========

3.1. Participants {#s0100}
-----------------

Between March 17, 2014, and May 22nd 2015, a total of 47 patients with SAD (mean ± SD age 31.8 ± 10.2 years; 18 women) were recruited and randomly assigned either to overt (*n* = 24) or covert (*n* = 23) SSRI treatment. One male participant assigned to the covert group did not provide fMRI-data and dropped out of treatment after a few days, limiting the statistical evaluation to 46 patients with complete outcome data. See [Fig. 1](#f0005){ref-type="fig"} for the-trial profile and [Table 1](#t0005){ref-type="table"} for descriptive characteristics.Fig. 1Trial profile.Fig. 1Table 1Descriptive characteristics.Table 1Overt SSRI\
(*n* = 24)Covert SSRI\
(*n* = 22)Statistic\
(df)pAge, years, mean (sd)31.0 (10.6)32.0 (9.7)t(44) = 0.330.74Sex, men, n (%)15 (62.5)13 (59.1)χ^2^(1) = 0.060.81Civil status, single, n (%)12 (50)7 (31.8)χ^2^(1) = 1.570.21Education \> 12 years, n (%)12 (50)7 (31.8)χ^2^(1) = 1.570.21Comorbidity, n (%)9 (37.5)13 (59.1)χ^2^(1) = 2.140.14 GAD1 (4.2)4 (18.2) Panic disorder--1 (4.5) Agoraphobia6 (25)5 (22.7) OCD, mild1 (4.2)-- Depression, mild5 (20.8)5 (22.7) Dysthymia2 (8.3)2 (9.1)Earlier psychological treatment, n (%)10 (41.7)9 (40.9)χ^2^(1) = 0.000.96Earlier psychotropic medication, n (%)4 (16.7)7 (31.8)χ^2^(1) = 1.450.23 SSRIs4 (16.7)6 (27.3) Venlafaxine--1 (4.5)[^2]

3.2. Pretreatment Evaluation {#s0110}
----------------------------

There were no significant differences between the overt and covert SSRI group before treatment on baseline demographics, disease characteristics ([Table 1](#t0005){ref-type="table"}), or on any primary or secondary outcome measure ([Table 2](#t0010){ref-type="table"}). Before randomization, significantly higher (t(42) = 6.58, p \< 0.0001) credibility ratings were given for SSRI treatment (M ± SD 29.77 ± 7.07) compared with "active placebo" according to the cover story (M ± SD 19.53 ± 9.29), see [Fig. 2](#f0010){ref-type="fig"} (top left). The overt and covert groups did not differ in their initial (pre-randomization) ratings of the two treatments (p \> 0.38).Fig. 2Top left: Initial credibility ratings for SSRI (escitalopram) and "active placebo" described as a neurokinin-1 antagonist in the cover story before randomization (50 = maximal credibility); Top right: Percentage of individuals meeting the criteria for clinically significant improvement on the Liebowitz Social Anxiety Scale (LSAS-SR); Lower panel: Time course of treatment response on the LSAS-SR. \*^)^ p \< 0.05, \*\*^)^*p* \< 0.01, \*\*\*^)^*p* \< 0.005.Fig. 2Table 2Clinical variables before in comparison to after treatment.Table 2Overt SSRI\
(n = 24)Covert SSRI\
(n = 22)F(1, 44) (between)*p*-Value (between)Partial η^2^ (between)Liebowitz Social Anxiety Scale self-report[a](#tf0005){ref-type="table-fn"}16.58\<0.00010.27 Pre (SD)83.71 (20.13)81.45 (17.82) Post (SD41.08 (17.91)60.00 (20.17) Paired *t*-test, *p*-Value10.71, p \< 0.0001 6.58, p \< 0.0001  Cohen\'s d/SD change[b](#tf0010){ref-type="table-fn"} (within)2.24/19.501.13/15.30STAI-S Anticipatory anxiety[a](#tf0005){ref-type="table-fn"}0.040. 840.001 Pre (SD)58.21 (9.01)60.91 (7.83) Post (SD)48.42 (12.02)51.73 (11.74) Paired t-test, p-value4.79, p \< 0.00014.03, p = 0.001 Cohen\'s d/SD change[b](#tf0010){ref-type="table-fn"} (within)0.92/10.010.93/10.69Social Phobia Scale2.970.090.06 Pre (SD)39.25 (14.10)39.23 (14.47) Post (SD)22.75 (15.07)28.91 (13.13) Paired *t*-test, p-value7.48, p \< 0.00013.59, p = 0.002 Cohen\'s d/SD change[b](#tf0010){ref-type="table-fn"} (within)1.12/10.810.75/13.48Social Interaction Anxiety Scale6.910.010.14 Pre (SD)54.92 (13.82)54.36 (10.92) Post (SD)36.08 (15.97)46.00 (13.11) Paired *t*-test, p-value6.77, p \< 0.00012.94, p = 0.008 Cohen\'s d/SD change[b](#tf0010){ref-type="table-fn"} (within)1.26/13.620.70/13.35Montgomery Åsberg Depression Rating Scale self-report5.400.020.11 Pre (SD)17.04 (7.23)14.91 (7. 60) Post (SD)7.38 (5.75)10.27 (5.28) Paired *t*-test, p-value6.09, p \< 0.00013.19, p = 0.004 Cohen\'s d/SD change[b](#tf0010){ref-type="table-fn"} (within)1. 47/7.780.70/6.82Beck Anxiety Inventory1.180.280.03 Pre (SD)19.92 (8.66)19.18 (7. 82) Post (SD)9.25 (6.94)11.18 (5.58) Paired t-test, p-value7.83, p \< 0.00013.84, p = 0.001 Cohen\'s d/SD change[b](#tf0010){ref-type="table-fn"} (within)1.36/6.681.18/9.78Quality Of Life Inventory8.370.0060.16 Pre (SD)0. 66 (1.62)0.87 (1.34) Post (SD)2.01 (1.25)1.10 (1.27) Paired t-test, p-value4.39, p = 0.00021.03, p = 0.32 Cohen\'s d/SD change[b](#tf0010){ref-type="table-fn"} (within)0.89/1.500.15/1.05[^3][^4][^5]

3.3. Primary Clinical Outcomes {#s0115}
------------------------------

Online assessments of LSAS-SR, yielded a significant Group × Time interaction (F(4,176) = 9.16, p \< 0.0001, ƞ^2^ = 0.17) in the repeated measures ANOVA, supporting larger improvement in the overt as compared to the covert SSRI arm, with a significant between-group difference emerging at week 3 (t(44) = 2.23, p = 0.03) -- see [Fig. 2](#f0010){ref-type="fig"} (lower panel). Accordingly, after treatment there were significantly more responders, i.e. individuals meeting the criteria for clinically significant improvement on the LSAS-SR, in the overt (12/24, 50%) than in the covert (3/22, 14%) SSRI arm (χ^2^(1) = 6.91, p = 0.009), [Fig. 2](#f0010){ref-type="fig"} (top right). For LSAS-SR, the (pre-post) effect size was *d* = 2.24 in the overt vs. *d* = 1.13 in the covert group. Anticipatory speech anxiety (STAI-S) ratings before the behavioral test did not change differently (pre-post) in the two groups, both improving with treatment ([Table 2](#t0010){ref-type="table"}).

3.4. Secondary Clinical Outcomes {#s0120}
--------------------------------

With regard to secondary clinical measures, both groups improved significantly from pre- to posttreatment on all measures with the exception of quality of life in the covert arm ([Table 2](#t0010){ref-type="table"}). There was a significant Group × Time interaction indicating better treatment outcome in the overt as compared to covert SSRI arm on measures of social interaction anxiety, depression and quality of life ([Table 2](#t0010){ref-type="table"}). Repeated measures MANOVA of all primary and secondary measures indicated a significant Group × Time (pre/post) interaction (Wilk\'s λ = 0.62, F(7,38) = 3.30, p = 0.008, ƞ^2^ = 0.38) in favor of overt SSRI.

3.5. Treatment Satisfaction {#s0125}
---------------------------

After nine weeks of treatment, participants in both groups were equally content with having participated in the study (M ± SD: overt = 3.33 ± 0.82; covert = 2.96 ± 0.70; *U* = 205, *p* = 0.09), but participants in the overt group were more likely to believe that their received treatment was good for SAD (M ± SD: overt = 6.96 ± 2.71; covert = 5.22 ± 2.87; *U* = 161, p = 0.01), more likely to recommend their treatment to a friend (M ± SD: overt = 7.25 ± 2.83; covert = 5.27 ± 3.38; *U* = 170, p = 0.04), and more prone to report a change towards a more positive attitude to their treatment during the course of the study (M ± SD: overt = 3.67 ± 1.09; covert = 3.09 ± 0.75; *U* = 183, p = 0.03) in comparison to the covert group.

3.6. Blood Serum Analyses {#s0130}
-------------------------

Blood serum analyses of escitalopram concentrations at the posttreatment fMRI indicated that all patients had taken their medication as intended (median \[25th--75th percentile\] 74.0 \[48.75--119.75\] nmol/l). At posttreatment, there were no significant differences between the overt vs. covert SSRI arm with regard to concentrations of escitalopram (t(44) = 1.62, p = 0.11), desmethylescitalopram (t(44) = 0.50, p = 0.62) or didesmethylescitalopram (t(44) = 0.27, p = 0.79).

3.7. Adverse Events {#s0135}
-------------------

The total number of recordered adverse events did not differ between the groups (t(44) = 1.40, p = 0.17), while there was a tendency (t(44) = 1.90, p = 0.06) for more adverse events that were deemed to be drug related in the overt (M ± SD 3.39 ± 2.62) as compared to the covert (2.22 ± 1.38) SSRI group. The most common adverse events were nausea, tiredness, headache, sleep- and sex-related problems. Events were generally mild to moderate, usually transient, and all were resolved at posttreatment.

3.8. Additional Measures {#s0140}
------------------------

See the Supplement regarding participants\' reactions to the reveal of the cover story, the psychiatrist\'s complementary evaluation, and comparisons of covert SSRI treatment with waiting-list and CBT data.

3.9. fMRI: Overt *vs.* Covert SSRI Administration {#s0150}
-------------------------------------------------

Amygdala ROI analysis did not yield significant between-group results while an exploratory whole-brain analysis indicated a differential neural treatment response with relatively increased (pre to post) reactivity to the emotional faces in the overt SSRI arm, and decreased reactivity in the covert group, in the bilateral posterior cingulate cortex, left mid temporal gyrus and left inferior frontal gyrus ([Table 3](#t0015){ref-type="table"}, [Fig. 3](#f0015){ref-type="fig"}). There were no significant group differences in the above regions before treatment.Fig. 3Top panel: Relatively increased neural reactivity after overt as compared to covert treatment with escitalopram in the bilateral posterior cingulate cortex as well as the left mid temporal and inferior frontal gyri, measured during the emotional face-matching paradigm. Lower panel: Interaction plots illustrating the neural changes in the four implicated cortical regions from pre to posttreatment in the overt (blue bars) as compared to the covert (red bars) group. Error bars reflect the standard error of the mean. AU refers to arbitrary units and BA refers to Brodmann area.Fig. 3Table 3Brain regions exhibiting altered neural reactivity as a function of overt (n = 24) or covert (n = 22) SSRI administration.Table 3ContrastMNI coordinateCluster size[a](#tf0015){ref-type="table-fn"}Z value*p* valueBrain regionxyzOvert \> covert SSRI R posterior cingulate gyrus (BA23)9− 282837804.58\< 0.0001 L mid temporal gyrus (BA39)− 30− 58255133.93\< 0.0001 L posterior cingulate gyrus (BA31)− 21− 28343513.83\< 0.0001 L inferior frontal gyrus (BA46)− 363512703.690.0001Covert \> overt SSRI ns[^6][^7]

3.10. Brain-behavior Correlations {#s0155}
---------------------------------

Follow-up analysis revealed that decreased social anxiety, as measured with LSAS-SR from pre- to posttreatment, was associated with reduced activation of the right amygdala (*x* = 33, *y* = − 1, *z* = − 29; *Z* = 2.70, k = 972 mm^3^, p = 0.003 - see [Fig. 4](#f0020){ref-type="fig"}, top panel) and increased activation of the posterior cingulate/precuneus region (*x* = − 18, *y* = − 31, *z* = 34, *Z* = 3.24, k = 216 mm^3^, p = 0.0006; *x* = 12, *y* = − 46, *z* = 16, *Z* = 3.10, k = 2133 mm^3^, p = 0.001; *x* = − 30, *y* = − 58, *z* = 28, *Z* = 2.85, k = 486 mm^3^; p = 0.002 - see [Fig. 4](#f0020){ref-type="fig"}, lower panel).Fig. 4Top panel: Positive correlation between reduced amygdala reactivity and reduced scores on the Liebowitz social anxiety scale (LSAS-SR) with treatment. Lower panel: Negative correlation between increased reactivity in the posterior cingulate cortex (PCC) and reduced scores on LSAS-SR with treatment. Color bars represent T-scores, brighter colors indicating stronger correlations. Blue circles indicate overt and red squares covert treatment with escitalopram.Fig. 4

3.11. Psychophysiological Interaction Analysis {#s0160}
----------------------------------------------

Based on the correlation between change in amygdala reactivity and symptom improvement (LSAS-SR) with treatment, psychophysiological interaction (PPI) follow-up analysis of group differences in amygdala connectivity was conducted with time-series fMRI data extracted from the obtained peak voxel (33, − 1, − 29) entered as a regressor together with task (faces vs. shapes) and the interaction between the two. The covert as compared to overt group, exhibited increased connectivity after treatment between the amygdala and right dorsal posterior cingulate cortex (x = 21, y = − 49, z = 40; Z = 3.62; 144 mm^3^, p \< 0.00001) and right insula (x = 45, y = − 22, z = 25; Z = 3.94; 144 mm^3^, p \< 0.00001) -- see [Fig. 5](#f0025){ref-type="fig"}.Fig. 5Psychophysiological interaction analysis showing increased connectivity between the amygdala and A) the right dorsal posterior cingulate cortex and B) the right insula, in the covert as compared to the overt group. Color bars represent T-scores, brighter colors indicating higher values.Fig. 5

4. Discussion {#s0165}
=============

The present study demonstrates that verbal instructions influence SSRI anxiolytic outcome and associated brain parameters. In contrast to previous studies (e.g., [@bb0050]), we used a randomized design with truthful vs. deceiving instructions to estimate the contribution of verbally induced expectancies to SSRI efficacy in SAD. Better clinical outcome was noted in the overt as compared to the covert SSRI group on the primary LSAS-SR measure, with a doubled (pre-post) effect size, more than tripled response rate (50% vs 14%), greater treatment satisfaction after 9 weeks, and superior improvement according to multivariate analysis of all primary and secondary outcome measures. Thus, the instructions given while prescribing SSRIs make a significant clinical difference. This is in accordance with previous literature showing that administering a treatment covertly is not as efficient as an open administration ([@bb0055]; [@bb0040]). For post-operative anxiety, covert administration of benzodiazepines has been reported to be ineffective, and experimental studies in pain have also shown that the needed doses to achieve satisfactory clinical outcomes are much higher when drugs are administered covertly ([@bb0055]; [@bb0040]). In fact, verbally-induced negative treatment expectancies may even abolish opioid-induced analgesia ([@bb0040]).

In SAD, we have previously demonstrated highly similar changes in brain activity and functional couplings for SSRI and placebo responders ([@bb0060], [@bb0065]), suggesting that expectancies of improvement could play an important role in SSRI treatment. Here, we show that overt administration of an SSRI is considerably more effective on the LSAS-SR, in comparison to covert administration suggesting that the efficacy of SSRIs may be highly dependent on psychological effects like positive expectancies, traditionally associated with placebo response. However, the groups improved equally on anticipatory anxiety before the public speaking challenge, and escitalopram administered covertly, when compared to arms from a previous RCT, was superior to a waiting-list condition and comparable to Internet-based CBT (see Supplement). While this must be interpreted cautiously in the absence of randomized comparisons, it is plausible that (covert) escitalopram possesses at least moderate anxiolytic properties that need to be augmented with psychosocially induced expectancies to reach full clinical potential. Overall, our results favor a biopsychosocial over a pure biomedical explanatory model for SSRI efficacy in SAD.

The clinical effect was accompanied by a differential neural response to treatment as measured with BOLD-fMRI during an emotional face-matching task. Although we did not observe significantly altered amygdala reactivity between groups, attenuated amygdala activity with treatment correlated significantly with reduced social anxiety, consistent with our previous studies ([@bb0060], [@bb0065]; [@bb0095]). After covert as compared to overt SSRI administration, the amygdala was more functionally coupled with other regions involved in emotion processing, including the insula and dorsal posterior cingulate cortex. Consistently, experimental studies suggest that the coupling between the amygdala and other nodes of the emotion processing network is stronger when fear memories are intact as compared to attenuated following disrupted reconsolidation ([@bb0005]). The most pronounced difference between groups in the present study was observed in the posterior cingulate cortex ([Table 3](#t0015){ref-type="table"}) and for the whole sample, increased reactivity within this region correlated with reduced social anxiety ([Fig. 4](#f0020){ref-type="fig"}). In depression, the posterior cingulate has been shown to be more activated after treatment both in SSRI- and placebo responders ([@bb0140]) and neuroplastic changes within the posterior cingulate have been reported after prolonged escitalopram/citalopram intake in healthy volunteers ([@bb0125]). Together with the adjacent precuneus, the posterior cingulate is a central node of the default mode network where altered neural activity has been associated with learning, memory, reward, and task engagement ([@bb0155]). The posterior cingulate is also consistently activated by emotional stimuli and suggested to be a region in which cognition and emotion interact ([@bb0130]). Thus, this may be a brain area where cognitive expectancies exert their effect on anxiety. However, elucidation of the mechanisms involved would require additional research e.g., with use of MRI-tasks that specifically manipulate expectancies together with mediation analyses.

There has been a sharp increase in neuroimaging studies of placebo in recent years ([@bb0035]), but very few have used deception to separate placebo from the drug effect or vice versa. Positron emission tomography studies have noted large additional effects of drug (methylphenidate) expectancy on brain glucose metabolism in cocaine abusers ([@bb0200]) and healthy volunteers ([@bb0205]). Similarly, fMRI trials of pain analgesia have demonstrated that expectancies, when combined with active treatment, yield substantial additional reduction in reported pain concomitantly with neurofunctional changes in pain processing brain regions ([@bb0040]; [@bb0180]; however, see [@bb0020]). But to our knowledge, the present neuroimaging trial is the first deception-placebo study of SSRIs and of prolonged treatment in patients.

Because the overt SSRI treatment yielded significantly higher initial credibility ratings, none of the participants reported doubts about the cover story, blood serum analyses showed equal compliance in both groups, and a differential clinical effect was obtained, we conclude that the verbal manipulation was successful and the study integrity well maintained. Among the limitations it should be noted, however, that the sample size was modest, imposing limits on statistical power. Also, long-term follow-up assessments of relapse rates were not possible to conduct. Moreover, we could not evaluate a group treated with placebo described as escitalopram and an overt placebo arm, i.e. the remaining two cells of the balanced placebo design ([@bb0165]). Thus, both drug and expectancies were not manipulated in our study and therefore we could not properly test whether drug and placebo effects are truly additive ([@bb0170]; [@bb0020]).

In conclusion, the present study demonstrates that the anxiolytic effect of escitalopram in SAD is highly sensitive to expectancies, as indicated by behavioral and neuroimaging evidence. Our study shows that verbal suggestions can have a profound influence on the anxiolytic effect of SSRIs. Thus, the presentation of a treatment may be as important as the treatment itself.
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[^2]: GAD = generalized anxiety disorder, OCD = obsessive compulsive disorder, SSRI = selective serotonin reuptake inhibitor.
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